Hong Kong Researchers Examine Synbiotic Preparation for Post-COVID-19 Syndrome in Randomized, Double Blind, Placebo-Controlled Study

According to the results of a randomized, double-blind, placebo-controlled clinical trial published in the Lancet, researchers in Hong Kong investigated treatment with SMI01, a synbiotic preparation of three lyophilised Bifidobacteria strains and three prebiotic compounds derived from the group’s metagenomics dataset as a method to alleviate the symptoms of Post-acute COVID-19 syndrome (PACS), determining that the intervention produced favorable changes in the gut microbiome, including increased diversity as well as an increase in short chain fatty acid producing bacteria after 6 months of treatment.

Click here to access the original article